Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tetrabenazine
Drug ID BADD_D02175
Description A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008.
Indications and Usage Treatment of hyperkinetic movement disorders like chorea in Huntington's disease, hemiballismus, senile chorea, Tourette syndrome and other tic disorders, and tardive dyskinesia
Marketing Status approved; investigational
ATC Code N07XX06
DrugBank ID DB04844
KEGG ID D08575
MeSH ID D013747
PubChem ID 6018
TTD Drug ID D09PJX
NDC Product Code 51224-425; 67386-421; 68180-409; 63827-1013; 65977-0085; 47335-277; 51407-481; 27241-177; 60505-3882; 65085-0064; 27241-176; 47335-179; 69452-117; 70436-102; 43598-395; 60505-3883; 70436-101; 57821-010; 51407-480; 68682-422; 31722-821; 43598-394; 51224-426; 69452-118; 69766-076; 31722-822; 67386-422; 42973-179; 68180-408; 68682-421; 64330-066; 64567-0025; 65015-831
UNII Z9O08YRN8O
Synonyms Tetrabenazine | Nitoman | Xenazine
Chemical Information
Molecular Formula C19H27NO3
CAS Registry Number 718635-93-9
SMILES CC(C)CC1CN2CCC3=CC(=C(C=C3C2CC1=O)OC)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Coordination abnormal17.02.02.0040.000538%Not Available
Crying19.04.02.002; 17.02.05.013; 12.02.11.001; 08.01.03.0050.003553%Not Available
Death08.04.01.0010.090550%
Decreased interest19.15.02.0040.001830%Not Available
Dehydration14.05.05.0010.005168%
Delirium19.13.02.0010.002261%
Dementia19.20.02.001; 17.03.01.0010.000538%Not Available
Depressed level of consciousness17.02.04.0020.002100%
Depressed mood19.15.02.0010.005760%Not Available
Depression19.15.01.0010.028102%
Diabetes mellitus14.06.01.001; 05.06.01.0010.000808%Not Available
Diarrhoea07.02.01.001--
Disorientation19.13.01.002; 17.02.05.0150.001830%Not Available
Disturbance in attention19.21.02.002; 17.03.03.0010.002261%
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Drooling17.02.05.0050.001184%Not Available
Drug ineffective08.06.01.0060.054965%Not Available
Drug interaction08.06.03.0010.002692%Not Available
Dry mouth07.06.01.002--
Dysarthria19.19.03.001; 17.02.08.0010.003284%
Dyskinesia17.01.02.0060.010821%
Dysphagia07.01.06.0030.011090%
Dyspnoea02.11.05.003; 22.02.01.004--
Dystonia17.01.03.0010.007806%Not Available
Dysuria20.02.02.002--
Eating disorder19.09.01.008; 14.03.01.0080.001454%Not Available
Ecchymosis23.06.01.001; 01.01.03.001; 24.07.06.002--Not Available
Emotional disorder19.04.02.0050.000808%Not Available
Epilepsy17.12.03.0020.000538%Not Available
Extrapyramidal disorder17.01.02.007--
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 6 Pages